「the 20」の検索結果
144件：56～60件目を表示
-
学会发表 | 研究与开发 | 千寿制药株式会社
o-Controlled Phase 3 Pivotal Study – Yuichi Hori, MD, PhD; Tomoyuki Wada, PhD; Kazunori Omatsu, BSc the 59th Congress of the European Societies of Toxicology 開催日：2025年9月14日～2025年9月17日 開催地：Athens, GREE...
http://www.senju.co.jp/chinese/rd/society/ -
Company Profile | About Senju | SENJU Pharmaceutical
6-0406 Date of Incorporation April 9, 1947 Capital 1,415,500,000 yen Board of Directors Chairman of the BoardYukoh Yoshida President ＆ CEOShuhei Yoshida Chief Operating OfficerTakeshi Sugisawa Managin...
http://www.senju.co.jp/english/about/outline.html -
ers: Osaka, Japan; President: Mr. Shuhei Yoshida) today announces that it has received approval for the marketing of “Mytear Lumify” (OTC drug requiring instruction by pharmacist, hereinafter this &qu...
https://www.senju.co.jp/system/files/content_news/2024-08/ENG_20240903.pdf -
. Launch and Distribution of “MIEr for BeelineMED” Senju Pharmaceutical Co., Ltd., hereby announces the commercial launch and distribution of “MIEr for BeelineMED” in Japan. MIEr for BeelineMED is cap...
https://www.senju.co.jp/system/files/content_news/2025-02/ENG_20250220.pdf -
. Launch and Distribution of “MIEr for BeelineMED” Senju Pharmaceutical Co., Ltd., hereby announces the commercial launch and distribution of “MIEr for BeelineMED” in Japan. MIEr for BeelineMED is cap...
https://www.senju.co.jp/system/files/content_news/2025-02/ENG_20250220_0.pdf